Structure Therapeutics, Inc. Sponsored ADR ( (GPCR)) has released its Q3 earnings. Here is a breakdown of the information Structure Therapeutics, Inc. Sponsored ADR presented to its investors.
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback